Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.
Catheter Cardiovasc Interv. 2019 Mar 1;93(4):692-698. doi: 10.1002/ccd.27904. Epub 2018 Sep 23.
MitraClip is an effective transcatheter therapy for mitral regurgitation (MR). However, MitraClip is challenging in commissural MR and the optimal therapeutic approach is unclear.
We describe a case series of six consecutive patients with severe commissural primary mitral regurgitation who underwent MitraClip insertion followed by an Amplatzer Vascular Plug (AVP) II occluder between the commissure and the MitraClip.
The procedure was successful in all patients. MR was reduced from severe to mild/trivial in 50% and moderate in 50% of cases. On 30-day follow-up, NYHA class had improved from III (6 patients) to I (2 patients), II (2 patients), and III (2 patients). The mean transmitral gradient was 2.5 ± 1.8 mmHg at baseline and 4.8 ± 2.6 mmHg following the procedure. One patient developed hemolysis immediately post procedure. The other five patients remained well during a median follow-up of 20 months (range 5-50 months) with no reported device dislodgement.
Elective treatment of severe commissural MR with a laterally or medially placed MitraClip coupled with an AVP II occluder between the clip and the commissure is feasible and safe. This approach may provide a useful management alternative in selected patients.
MitraClip 是一种治疗二尖瓣反流(MR)的有效经导管治疗方法。然而,在二尖瓣瓣环交界区病变所致的二尖瓣反流中,MitraClip 的应用具有挑战性,且最佳治疗方法尚不清楚。
我们描述了 6 例连续的严重交界区原发性二尖瓣反流患者的病例系列,这些患者接受了 MitraClip 植入术,随后在交界区和 MitraClip 之间放置了 Amplatzer Vascular Plug(AVP)II 封堵器。
所有患者的手术均成功。50%的患者 MR 由重度减轻至轻度/微量,50%的患者 MR 由重度减轻至中度。30 天随访时,NYHA 心功能分级从 III 级(6 例)改善为 I 级(2 例)、II 级(2 例)和 III 级(2 例)。基线时的平均跨瓣压差为 2.5±1.8mmHg,术后为 4.8±2.6mmHg。1 例患者术后即刻发生溶血。其余 5 例患者在中位随访 20 个月(5-50 个月)期间情况良好,无报道的器械移位。
对于外侧或内侧放置的 MitraClip 治疗严重交界区 MR,并在夹子和交界区之间放置 AVP II 封堵器,是可行和安全的。这种方法可能为特定患者提供一种有用的治疗选择。